Evidence is emerging to support combination systemic therapies on a backbone of immune checkpoint inhibition to overcome resistance to single-agent PD-1/PD-L1/CTLA-4 blockade in pancreatic cancer. Here, CD274 is linked to pancreatic neoplasm.